BCL2L1 and acute myeloid leukemia: BCL2 inhibitor + MCL1 inhibitor (tested in AMKL and non-AMKL AML models) (Aid et al., 2023); BCL-xL inhibitor + JAK inhibitor (tested in AMKL and non-AMKL AML models) (Kuusanmaki et al., 2023)